R&D | May 25, 2026
AstraZeneca to showcase cancer pipeline push at ASCO 2026
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
Highlighting KEYTRUDA & expanding cancer pipeline
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
This is an exciting and meaningful milestone for GRIN Therapeutics
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
The company says the product will now be distributed exclusively through Anovo Specialty Pharmacy
Subscribe To Our Newsletter & Stay Updated
